Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

ndicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 The National Space Biomedical ... Center for Space Radiation Research (CSRR) under the leadership ... an Associate Professor of Pharmaceutical Sciences within the University ... Division of Radiation Health. She is located in ... a team of investigators working across four U.S. institutions, ...
(Date:7/22/2014)... , July 22, 2014  Decision Resources Group finds that ... Canada will remain relatively stagnant at a value ... fact that percutaneous coronary intervention (PCI) volumes are growing faster ... markets, such as the United States ... largely driven by the increase in penetration of PCI procedures ...
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds ... (MS) patients currently treated with Biogen Idec,s ... experienced flushing and/or gastrointestinal events while on ... currently experiencing these side effects, signifying either ... management of such events. In the end, ...
Breaking Medicine Technology:Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3
... 14 New England Biolabs (NEB) has launched ... to simplify DNA methylation analysis for epigenetics researchers. ... of the current methods, including the lack of ... of 5-hydroxymethlcytosine (5-hmC) in the epigenome. ...
... Fe and Femcon® Fe... -- ARDEE, Ireland, Oct. 14 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome 2Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 2Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 3Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 4Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 5Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 6Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 7Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 8Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 9Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 10
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
(Date:7/22/2014)... Robert E. Marc, Ph.D., director of research at the ... been named by the International Society of Eye Research ... Research Foundation,s 2014 Paul Kayser International Award in Retina ... scientist who has made a significant contribution to the ... being presented this week at the ISER Biennial Meeting ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
(Date:7/22/2014)... Latin American Conference on Lung Cancer (LALCA 2014) will ... Peru. , Lung Cancer is still the leading cause ... Building on the success of the previous conferences in ... will discuss the science and advances in the treatment ... and Latin America in particular. , With tobacco being ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... human body, HOUSTON, Sept. 25 Can you ... Simply visit The John P. McGovern Museum of Health ... explore the latest,exhibit -- Sesame Street Presents: The Body ... October 4, 2007 and January 13, 2008.,The exhibit offers ...
... 25 A Place for Mom, the nation,s largest,referral ... that John,Temple, Chief Operating Officer was named to the ... The 40 Under 40 List is the Pacific Northwest ... They look for,nominees that work hard to drive the ...
... Phase II data presented today suggest that ZD4054, a ... with Hormone Resistant Prostate Cancer (HRPC), could offer a ... HRPC who were asymptomatic or mildly symptomatic for pain.1 ... percent reduction in the risk of death compared to ...
... 25 ThermoSpas, the country,s,largest hot tub retailer, ... chronically,ill children to give specially-designed therapeutic hot tubs ... program, the company will donate 12,ThermoSpas hot tubs ... who will benefit,from warm water therapy. ThermoSpas encourages ...
... Continuum Health Partners Selects Ericom(R) PowerTerm(R) WebConnect for ... ... 25 Continuum Health Partners, a,New York-based non-profit hospital system, ... of Continuum,s strategy to,provide doctors and staff with secure, on-demand ...
... youngsters to stay healthy, , , TUEDAY, Sept. 25 (HealthDay News) ... and way too much junk food are pushing U.S. children ... new studies finds. , The studies -- published in a ... -- show the myriad challenges youngsters face every day ...
Cached Medicine News:Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 2Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 3Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 4Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 5Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 6Health News:A Place for Mom COO Makes Seattle's 40 Under 40 List 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 3Health News:Photos: America's Chronically Ill Children Have New Hope with 'Hot' Gift 2Health News:Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization 2Health News:Junk Food, TV Driving Kids to Obesity 2Health News:Junk Food, TV Driving Kids to Obesity 3Health News:Junk Food, TV Driving Kids to Obesity 4
... Laboratories offers a comprehensive line of pregnancy ... and urine in convenient one-step stick and ... testing options. Clearview Easy HCG is a ... stick format. Clearview HCG II provides ...
... is based on sequential binding of HCG ... (specific for the *-chain of HCG) immobilized ... for the *-chain of HCG) conjugated to ... step, chromogenic substrate is added and colors ...
... Laboratories offers a comprehensive line of pregnancy ... and urine in convenient one-step stick and ... testing options. Clearview Easy HCG is a ... stick format. Clearview HCG II provides ...
For the quantitative determination of Glycohemoglobin in blood....
Medicine Products: